198 related articles for article (PubMed ID: 18729777)
1. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants.
Keitel WA; Atmar RL; Nino D; Cate TR; Couch RB
J Infect Dis; 2008 Oct; 198(7):1016-8. PubMed ID: 18729777
[TBL] [Abstract][Full Text] [Related]
2. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
[TBL] [Abstract][Full Text] [Related]
5. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
[TBL] [Abstract][Full Text] [Related]
6. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 May; 58(19):521-4. PubMed ID: 19478718
[TBL] [Abstract][Full Text] [Related]
7. Immunology. Prime, boost, and broaden.
Doms RW
Science; 2010 Aug; 329(5995):1021-2. PubMed ID: 20798304
[No Abstract] [Full Text] [Related]
8. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.
Hancock K; Veguilla V; Lu X; Zhong W; Butler EN; Sun H; Liu F; Dong L; DeVos JR; Gargiullo PM; Brammer TL; Cox NJ; Tumpey TM; Katz JM
N Engl J Med; 2009 Nov; 361(20):1945-52. PubMed ID: 19745214
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.
Oh CE; Lee J; Kang JH; Hong YJ; Kim YK; Cheong HJ; Ahn YJ; Kim SH; Lee HJ
Vaccine; 2010 Aug; 28(36):5857-63. PubMed ID: 20600483
[TBL] [Abstract][Full Text] [Related]
10. Failure of protection and enhanced pneumonia with a US H1N2 swine influenza virus in pigs vaccinated with an inactivated classical swine H1N1 vaccine.
Vincent AL; Lager KM; Janke BH; Gramer MR; Richt JA
Vet Microbiol; 2008 Jan; 126(4):310-23. PubMed ID: 17719188
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
[TBL] [Abstract][Full Text] [Related]
12. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination.
Subbramanian RA; Basha S; Shata MT; Brady RC; Bernstein DI
Vaccine; 2010 Dec; 28(52):8258-67. PubMed ID: 21050903
[TBL] [Abstract][Full Text] [Related]
13. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
Taylor DN; Treanor JJ; Strout C; Johnson C; Fitzgerald T; Kavita U; Ozer K; Tussey L; Shaw A
Vaccine; 2011 Jul; 29(31):4897-902. PubMed ID: 21596084
[TBL] [Abstract][Full Text] [Related]
14. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
15. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
Goji NA; Nolan C; Hill H; Wolff M; Noah DL; Williams TB; Rowe T; Treanor JJ
J Infect Dis; 2008 Sep; 198(5):635-41. PubMed ID: 18694338
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus.
Loeffen WL; de Vries RP; Stockhofe N; van Zoelen-Bos D; Maas R; Koch G; Moormann RJ; Rottier PJ; de Haan CA
Vaccine; 2011 Feb; 29(8):1545-50. PubMed ID: 21219983
[TBL] [Abstract][Full Text] [Related]
17. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
[TBL] [Abstract][Full Text] [Related]
18. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
Treanor JJ; Schiff GM; Couch RB; Cate TR; Brady RC; Hay CM; Wolff M; She D; Cox MM
J Infect Dis; 2006 May; 193(9):1223-8. PubMed ID: 16586358
[TBL] [Abstract][Full Text] [Related]
19. Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine.
Heckler R; Baillot A; Engelmann H; Neumeier E; Windorfer A
Intervirology; 2007; 50(1):58-62. PubMed ID: 17164559
[TBL] [Abstract][Full Text] [Related]
20. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies.
Lo CY; Wu Z; Misplon JA; Price GE; Pappas C; Kong WP; Tumpey TM; Epstein SL
Vaccine; 2008 Apr; 26(17):2062-72. PubMed ID: 18378366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
